Table 1.
Clinical characteristics of 83 patients with arthroscopy
| Variables |
Total |
ACPA positive |
ACPA negative |
P value |
|---|---|---|---|---|
| Number = 83 | Number = 64 | Number = 19 | ||
| Sex (Female%) |
62 |
64 |
58 |
0.62 |
| Age at arthroscopy (Mean, SD) |
55.98 ± 12.7 |
55.29 ± 12.8 |
58.23 ± 12.3 |
0.47 |
| Disease duration to arthroscopy (Median, IQR 25 to 75) months |
45.50 (10.8–122.1) |
34.56 (8.8–122.0) |
79.0 (15.1–126.8) |
0.27 |
| Rheumatoid factor (%) |
78 |
87 |
47 |
<0.001* |
| Extra-articular disease (%) |
31 |
35 |
20 |
0.28 |
| Erosive disease (%) |
74 |
72 |
76 |
0.73 |
| CRP mg/dl (Median, IQR 25 to 75) |
2.32 (1.0–5.3) |
2.95 (1.0–5.9) |
1.43 (0.7–3.7) |
0.21 |
| ESR mm (Median, IQR 25 to 75) |
32 (16.0– 64.0) |
37 (17.5–70.0) |
26 (14.7–39) |
0.07 |
| DAS28 (Median, IQR 25 to 75) |
4.74 (3.6–5.5) |
4.81 (3.7–5.5) |
4.74 (3.2–5.5) |
0.52 |
| mHAQ (Median, IQR 25 to 75) |
1.19 (0.5–1.5) |
1.25 (0.6–1.6) |
0.56 (0.2–0.7) |
0.10 |
| Number of DMARDs (ever), Mean (SD) |
2.20 (1.1) |
2.20 (1.1) |
1.86 (1.1) |
0.89 |
| Methotrexate (%), ever |
88.4 |
88.9 |
88.7 |
0.98 |
| Biologic treatment (%, before arthroscopy) ever | 40.6 | 40.0 | 42.0 | 0.85 |
ACPA, anti citrullinated peptide/protein antibodies; CRP, C-reactive protein; DAS-28, disease activity score -28 joints; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; IQR, interquartile range; mHAQ, Modified Health Assessment Questionnaire, SD, standard deviation; SJC, swelling joint count; TJC, tender joint count. *p value is significant if <0.05.